KB-1086

REGN5458-CD3-hIgG1

Background

REGN5458, a human bispecific antibody that binds to BCMA and CD3, efficiently activates T cells and induces polyclonal T cell killing of myeloma cell lines with a range of BCMA cell-surface densities, and also induces cytotoxicity of primary human plasma cells.

Specifications

Catalog Number:
KB-1086
Cell Line Name:
REGN5458-CD3-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD3
Species Reactivity:
Human
Application:
ELISA | FACS | Function assay
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | Function assay

References

1.Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM). Presented at: 19th Annual International Myeloma Society Meeting; August 25-27, 2022; Los Angeles, CA. Abstract OAB-056.
Please enable JavaScript in your browser to complete this form.